INZY,Inozyme Pharma, Inc. | Healthcare

Healthcare

INZY

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Inozyme Pharma, Inc.INZY

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases in the United States.

The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein, which is in Phase 1/2 clinical trials for the treatment of ENPP1 and ABCC6 deficiency, as well as for the treatment of calciphylaxis.

It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Latest News >

Reckitt cuts forecast as US tornado damage hits baby formula sales

Jul 24, 2024

July 24 (Reuters) - British consumer goods group Reckitt lowered its full-year sales growth forecast for 2024 on Wednesday, due to supply disruptions at its infant formula business after tornado damaged a third-party warehouse in the U.S. Reckitt, which makes Dettol and Lysol disinfectants, also said it had missed like-for-like net sales growth expectations for the second quarter. The Mount...

Informa agrees $1.6 billion deal for Cannes Lions owner Ascential

Jul 23, 2024

LONDON, July 24 (Reuters) - Britain's Informa ( IFPJF ) said on Wednesday it had agreed to buy Cannes Lions Festival owner Ascential ( AIAPF ) for 1.2 billion pounds ($1.6 billion), adding the prominent advertising industry conference to its portfolio of events. Ascential ( AIAPF ), which also owns the Money20/20 fintech events, said on Tuesday after the market...

Tesla, AT&T And 3 Stocks To Watch Heading Into Wednesday

Jul 24, 2024

With U.S. stock futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects AT&T Inc. ( T ) to report quarterly earnings at 57 cents per share on revenue of $29.92 billion before the opening bell, according to data from Benzinga Pro. AT&T ( T ) shares...

JGB yields climb as BOJ meet, weak auction spur caution

Jul 23, 2024

TOKYO, July 24 (Reuters) - Japanese government bond yields rose on Wednesday as a poorly received auction of 40-year debt left investors unsettled, who were already cautious ahead of a crucial Bank of Japan policy meeting next week. The 40-year JGB yield rose 3.5 basis points (bps) to 2.460%, with a measure of demand at the auction falling from the...